Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Eksterne analyser

Ovzon: US a challenge, but strong outlook - ABG

Ovzon

Dette er en ekstern analyse og afspejler ikke nødvendigvis vores perspektiv eller værdier.

Download analyse (PDF)
- Strong Q2; sales +148% y-o-y and positive EBIT
- We make small EBIT revisions
- Strong near-term outlook, 32x-16x '25e-'26e EV/EBIT


Strong Q2 results

With sales +148% y-o-y and EBIT of SEK 27m (vs. SEK -17m in Q2'24), Ovzon delivered a strong Q2. This improvement was driven by recent contracts; in particular the SEK 1bn order from the Swedish Defence Materiel Administration (FMV), which has been a real game changer for Ovzon. We estimate that only ~SEK 65m of the 24-month contract has so far been recognised, and it should also be noted that another SEK 72m follow-up contract was signed after the end of the quarter. This means that the SEK 1.2bn Q2 backlog provides a strong outlook and comparably good visibility of estimates. Importantly, Ovzon demonstrated significant operational leverage on improved sales, driven by a 20pp GM expansion (due to increased capacity on Ovzon-3) and rigorous opex control.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.